Summary Report: IDC Stakeholder Community Meeting - 19 October 2026, Online
Summary of online meeting held 19 October 2026
Beyond childhood: why lifelong vaccination is a frontline defence against chronic disease
Guest article by the World Federation of Public Health Associations (WFPHA)
Finding risk before disease: how the Safe Hearts Plan aims to transform prevention
Following the Safe Hearts Plan JACARDI Insights
Effectiveness of nirsevimab immunisation on invasive pneumococcal disease in children nationwide in France: an observational cohort study
These findings suggest an additional benefit of nirsevimab implementation beyond RSV disease prevention, but further studies are needed.
Recombinant Influenza Vaccine and Influenza Outbreaks in US Nursing Homes: Results From a Pragmatic Cluster-Randomized Clinical Trial
These findings suggest that recombinant influenza vaccines may provide clinically meaningful facility-level benefits in long-term care settings during seasons with substantial influenza circulation.
High-dose vs standard-dose influenza vaccine in heart failure: the FLUNITY-HD pooled analysis
The results of prior randomized trials investigating the potential role of influenza vaccination in preventing severe clinical events in various HF populations have been mixed.
Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2
Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk.
Article
Scientific Papers
Viral pneumonia in older adults: from immunosenescence and chronic disease to vaccine-modifiable risk
This narrative review examines viral pneumonia in older adults at the intersection of immunosenescence, frailty, multimorbidity and immune compromise.
